Solstice Biologics says that is has solved the problem of delivering RNAi into a cell with its new 'limitless' RNAi technology. The technology employs a covalently bound molecule to form an RNAi pro-drug -- called Ribonucleic Neutrals (RNN). The pro-drug crosses the membrane and is converted by an intracellular enzyme into an active RNAi drug.
Company founder, Steven Dowdy, says "The only reason that these Big Pharmas got out of the RNAi business was because of delivery. Therefore by solving the delivery problem it will likely bring most of them back inside to take a second look."
Previously, Novartis, Roche and others have withdrawn from clinical programs in the RNAi area. Seemingly Solstice believes, 'if you build it they will come'. We'll see. See In-Pharmatechnologist.
Posted by Bruce Lehr Jan 15th 2013.